Virginia Retirement Systems ET AL cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) by 5.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 35,600 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Virginia Retirement […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price target reduced by investment analysts at Canaccord Genuity Group from $31.00 to $20.00 in a report released on Wednesday, The Fly reports. Canaccord Genuity Group’s target price would indicate a potential upside of 57.98% from the stock’s current price. Other equities research analysts have also issued […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) CFO Mark C. Schneyer sold 653 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $17.91, for a total value of $11,695.23. Following the transaction, the chief financial officer now directly owns 3,342 shares in the […]
Brokerages expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) to post sales of $131.19 million for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for ACADIA Pharmaceuticals’ earnings. The lowest sales estimate is $126.00 million and the highest is $135.50 million. ACADIA Pharmaceuticals reported sales of $115.22 million during […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) has earned a consensus recommendation of “Hold” from the twenty analysts that are covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered […]